The CHANCE-2 trial results demonstrated that among Chinese patients with minor ischemic stroke or transient ischemic attack (TIA) carrying CYP2C19 LoF alleles, ticagrelor was associated with a modestly reduced risk of stroke at 90 days compared to clopidogrel. The gene discussed is CYP2C19; the disease is stroke disorder.